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cTATE-OF-THE-ART PAPER1769Infiltrative Cardiovascular Diseasesames B. Seward, Grace Casaclang-Verzosa
nfiltrative cardiomyopathies are characterized by deposition of abnormal substances that cause
he ventricular walls to become progressively rigid, thereby impeding ventricular filling. Some
nfiltrative cardiac diseases increase ventricular wall thickness, while others cause chamber
nlargement with secondary wall thinning. Increased wall thickness, small ventricular volume,
nd occasional dynamic left ventricular outflow obstruction can outwardly appear similar to
onditions with true myocyte hypertrophy. This paper by Seward and Casaclang-Verzosa
eviews the 9 common infiltrative cardiomyopathies, including the clinical presentation and
unctional and morphologic features.LINICAL RESEARCH1780Differences Between Beta-Blockers in Patients With CHF and COPDndrew Jabbour, Peter S. Macdonald, Anne M. Keogh, Eugene Kotlyar, Soren Mellemkjaer,
athie F. Coleman, Maros Elsik, Henry Krum, Christopher S. Hayward
abbour and colleagues sought to determine the effects of switching between 1-selective and
onselective beta-blockers in patients with chronic heart failure (CHF) and chronic
bstructive pulmonary disease (COPD). A triple-crossover trial in 51 subjects with a mean
jection fraction of 37% was conducted. Subjects were switched between carvedilol,
etroprolol succinate, and bisoprolol, dose-matched, for 6 weeks each. N-terminal pro-
ormone brain natriuretic peptide (NT-proBNP) and augmented pressure were significantly
ower on carvedilol than metoprolol or bisoprolol. In subjects with COPD, forced expiratory
olume in 1 s was lowest on carvedilol and highest on bisoprolol. Switching between
1-selective beta-blockers and the nonselective beta-blocker carvedilol results in demonstrable
hanges in airway function and NT-proBNP levels.(continued on page A-22)
APRIL 27, 2010 (continued) A-22CD
R
T
v
c
e
l
m
m
i
p
C
N
M
P
L
T
f
3
s
f
t
r
w
C
C
D
B
T
p
i
m
s
(
d
i
ELINICAL RESEARCH1788Reverse Remodeling With CRT Plateaus After 6 Monthsavid Verhaert, Richard A. Grimm, Chirapa Puntawangkoon, Kathy Wolski, Sabe De, Bruce L. Wilkoff,
andall C. Starling, W. H. Wilson Tang, James D. Thomas, Zoran B. Popovic´
his study by Verhaert and colleagues sought to define the long-term course of left
entricular remodeling induced by cardiac resynchronization therapy (CRT). A total of 313
onsecutive patients who underwent CRT were followed for major clinical events and
chocardiographic parameters. Subjects who did not suffer an adverse event had a decrease in
eft ventricular end-systolic volume index (LVESVi) of 0.11 ml/m2/day during the first 6
onths; whereas LVESVi remained unchanged in patients with adverse events. Beyond 6
onths, LVESVi remained unchanged in patients with no events, but continued to increase
n those with adverse events. CRT can induce reverse remodeling for 6 months after the
rocedure.LINICAL RESEARCH
1796o Benefit to Maintaining Sinus Rhythm in Patients
With HF and Left Ventricular Dysfunctionario Talajic, Paul Khairy, Sylvie Levesque, Stuart J. Connolly, Paul Dorian, Marc Dubuc,
eter G. Guerra, Stefan H. Hohnloser, Kerry L. Lee, Laurent Macle, Stanley Nattel, Ole D. Pedersen,
ynne Warner Stevenson, Bernard Thibault, Albert L. Waldo, D. George Wyse, Denis Roy
alajic and colleagues randomized over 1,300 patients with atrial fibrillation (AF), ejection
raction 35%, and heart failure symptoms to a rhythm- or rate-control strategy. Overall,
2% of patients died and 29% experienced worsening heart failure. There were no statistically
ignificant differences in cardiovascular mortality, all-cause death, or worsening heart failure
or patients assigned to a rhythm- or rate-control strategy. Further analyses devised to isolate
he effect of the actual rhythm also failed to show any significant differences. Neither a
hythm-control strategy or the presence of sinus rhythm lead to better outcomes in patients
ith AF and congestive heart failure.LINICAL RESEARCH
1803RT Devices Diagnostic Parameters Can Identify
Those at Risk for HF Hospitalizationavid J. Whellan, Kevin T. Ousdigian, Sana M. Al-Khatib, Wenji Pu, Shantanu Sarkar, Charles B. Porter,
ehzad B. Pavri, Christopher M. O’Connor, for the PARTNERS Study Investigators
he current generation of Medtronic (Minneapolis, Minnesota) implantable devices for
atients with heart failure (HF) have the capability of storing diagnostic data that may
dentify patients with early HF decompensation. Whellan and colleagues report that a
onthly assessment for a fluid index 100, or 2 other potential markers of decompensation,
uch as low patient activity, high night heart rate, or low cardiac resynchronization therapy
CRT) pacing, could identify an increased short-term risk for HF hospitalization. The use of
evice diagnostics may help identify a group of patients who could benefit from more
ntensive HF care.
ditorial Comment: J. Malcolm O. Arnold, Lorne J. Gula, p. 1811(continued on page A-24)
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ELINICAL RESEARCH1814Findings on CPX Predict Mortality for Patients With Heart Failureing-Guo Sun, James E. Hansen, John F. Beshai, Karlman Wasserman
un and colleagues sought to identify better predictors of early death and hospitalization in
atients with left ventricular chronic heart failure (CHF). The potential predictors, derived
rom cardiopulmonary exercise testing (CPX), were compared with other commonly used
ardiovascular measurements. The single best predictor of mortality was an elevated lowest
˙ E/V˙CO2 (155% predicted). Oscillatory breathing, defined as 3 or more consecutive cyclic
uctuations of ventilation during CPX, occurred in approximatey one-half of the subjects.
dding the presence or absence of OB to V˙E/V˙CO2 increased the odds ratio for mortality
rom 9.4 to 39. These findings confirm that CPX parameters are powerful prognosticators of
arly mortality and morbidity in CHF patients, especially the combination of elevated lowest
˙ E/V˙CO2 and OB.ditorial Comment: Jerome L. Fleg, p. 1824LINICAL RESEARCH1826Improved Quality of Life and Functional Status With Continuous Flow LVADsoseph G. Rogers, Keith D. Aaronson, Andrew J. Boyle, Stuart D. Russell, Carmelo A. Milano,
rancis D. Pagani, Brooks S. Edwards, Soon Park, Ranjit John, John V. Conte, David J. Farrar,
ark S. Slaughter, for the HeartMate II Investigators
ogers and colleagues assessed the impact of continuous-flow left ventricular assist devices
LVADs) on functional capacity and heart failure-related quality of life. The continuous flow
evices are smaller and quieter than pulsatile-flow LVADs, but there is concern that the
onphysiologic flow may be detrimental in the long term. Compared to baseline, LVAD
atients demonstrated early and sustained improvements in functional status and quality of
ife. Eighty percent of patients improved from New York Heart Association functional class
V symptoms to class I or II, with benefits sustained at 24 months. These correlated with
ubstantial improvements in 6-min walk distance. Use of a continuous flow LVAD in
dvanced heart failure patients results in clinically relevant improvements in functional
apacity and heart failure-related quality of life.
ditorial Comment: Randall C. Starling, p. 1835(continued on page A-26)
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1837F Disease Management Programs
May Be Detrimental for Depressed Patientsiny Jaarsma, Ivonne Lesman-Leegte, Hans L. Hillege, Nic J. Veeger, Robbert Sanderman,
irk J. van Veldhuisen, on behalf of the COACH Investigators
epressive symptoms are a risk factor for nonadherence with the heart failure (HF) regimen,
uch as medication, diet, and exercise. HF disease management programs (DMPs) seek to
mprove adherence; these programs assume an active role for motivated patients. Jaarsma and
olleagues compared the outcomes for patients with and without depressive symptoms
nrolled in a DMP trial. Over 30% of the subjects reported depressive symptoms. In patients
ithout depressive symptoms, DMP resulted in a trend for lower incidence of the primary
nd point (hazard ratio: 0.8), while the opposite was observed in patients with depressive
ymptoms (hazard ratio: 1.3). Patients with symptoms of depression do not benefit from
MP.CLINICAL TRIALS LINICAL TRIALS1844Infusing hANP During CPB Leads to Long-Term Beneftskira Sezai, Mitsumasa Hata, Tetsuya Niino, Isamu Yoshitake, Satoshi Unosawa, Shinji Wakui,
ishu Fujita, Tadateru Takayama, Yuji Kasamaki, Atsushi Hirayama, Kazutomo Minami
ezai and colleagues report on the long-term outcomes of patients with left ventricular
ysfunction undergoing coronary artery bypass graft surgery that were randomized to
ontinuous infusion of human atrial natriuretic peptide (hANP) or placebo at the start of
ardiopulmonary bypass (CPB). Perioperative complications were significantly less frequent in
he hANP group. The cardiac death-free rate was approximately 10% lower at both 5 and 8
ears. The estimated glomerular filtration rate was significantly higher in the hANP group
tarting at 1 month and maintained throughout follow-up. The hANP infusion appears to
itigate the damage caused by CPB and may have a role in the perioperative management of
atients undergoing cardiac surgery.ditorial Comment: Adriaan A. Voors, Dirk J. van Veldhuisen, p. 1852INTERVENTIONAL CARDIOLOGY NTERVENTIONAL CARDIOLOGY1854DES Effective for Chronic Total Occlusionsumberto J. Colmenarez, Javier Escaned, Cristina Ferna´ndez, Liliana Lobo, Sara Cano,
uan G. del Angel, Fernando Alfonso, Pilar Jimenez, Camino Bañuelos, Nieves Gonzalo, Eulogio Garcı´a,
osana Herna´ndez, Carlos Macaya
olmenarez and associates compared the efficacy and safety of drug-eluting stent (DES) compared
o bare-metal stents (BMS) for chronic total occlusions (CTO) by performing a systematic review
nd meta-analysis. Fourteen comparative studies were identified (n  4,394). When compared
ith BMS, DES significantly reduced the risk of MACE and target vessel revascularization by
ore than 50%. Rates of death and myocardial infarction were not significantly different. Use of
ES in CTO recanalization is associated with significantly lower MACE, TVR, restenosis, and
tent reocclusion than BMS.(continued on page A-27)
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fALVULAR HEART DISEASE1867Metabolic Syndrome Seems to Predispose to LV Hypertrophynik Pagé, Jean G. Dumesnil, Marie-Annick Clavel, Kwan L. Chan, Koon K. Teo, James W. Tam,
atrick Mathieu, Jean-Pierre Després, Philippe Pibarot, on behalf of the ASTRONOMER Investigators
agé and colleagues studied the relationship between metabolic syndrome (MetS) and left
entricular (LV) geometry and function in patients with asymptomatic aortic stenosis (AS).
he ASTRONOMER study enrolled patients with asymptomatic moderate to severe AS.
ne-third had systemic hypertension and one-quarter had MetS. Patients with MetS had
igher LV mass index, relative wall thickness ratio, and prevalence of LV concentric
ypertrophy, and lower early diastolic and systolic mitral annular myocardial velocities
ompared to those without MetS. MetS is independently associated with more pronounced
V concentric hypertrophy, and worse myocardial function in patients with AS.HYPERTENSION YPERTENSION1875Impact of Atenolol- or Amlodipine-Based Regimens on Diastolic Functionobyn J. Tapp, Andrew Sharp, Alice V. Stanton, Eoin O’Brien, Nishi Chaturvedi, Neil R. Poulter,
eter S. Sever, Simon A. McG. Thom, Alun D. Hughes, Jamil Mayet, on behalf of the ASCOT Investigators
app and associates used data from the ASCOT trial to determine if antihypertensive
herapies differ in their effect on left ventricular (LV) diastolic function. For this trial, almost
0,000 subjects were randomized to atenolol- or amlodipine-based antihypertensive treatment
nd conventional and tissue Doppler echocardiography were performed after 1 year. On-
reatment blood pressure (BP) was similar in both groups. Treatment with the amlodipine-
ased regimen was associated with higher early diastolic mitral annular velocity (E’), lower
lasma BNP, lower E/E’, a smaller atrial diameter, and a shorter E-wave deceleration time.
ndividuals receiving treatment with an amlodipine-based regimen had better diastolic
unction than those treated with an atenolol-based regimen, independent of BP reduction.
